Microsatellite Instability and Metastatic Colorectal Cancer - A Clinical Perspective
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F22%3A10444902" target="_blank" >RIV/00216208:11110/22:10444902 - isvavai.cz</a>
Alternative codes found
RIV/00064190:_____/22:N0000002
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=8i3UtwCalZ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=8i3UtwCalZ</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2022.888181" target="_blank" >10.3389/fonc.2022.888181</a>
Alternative languages
Result language
angličtina
Original language name
Microsatellite Instability and Metastatic Colorectal Cancer - A Clinical Perspective
Original language description
Approximately 4-5% of patients with metastatic colorectal cancer (mCRC) have mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) tumours. These tumours present challenges in the clinical practice due to variant response to fluoropyrimidine-based chemotherapy and, perhaps, also non-immunologic targeted therapies. Recently, a breakthrough in the treatment of dMMR/MSI-H mCRC has been achieved with several clinical trials showing dramatic long-term benefit of immunotherapy using checkpoint inhibitors. Nevertheless, several questions remain regarding the optimisation of immunotherapy regimens and the use of biomarkers to identify populations set to derive the greatest benefit from immunotherapy. Combination regimens and/or the use of immunotherapy as a maintenance after induction non-immunologic systemic therapy may be the way forward to improve outcomes.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Oncology [online]
ISSN
2234-943X
e-ISSN
2234-943X
Volume of the periodical
12
Issue of the periodical within the volume
April
Country of publishing house
CH - SWITZERLAND
Number of pages
6
Pages from-to
888181
UT code for WoS article
000794416500001
EID of the result in the Scopus database
2-s2.0-85130164590